With This Company’s Potential Treatment for an Unmet Medical Need, the Sky’s the Limit

Actinium Pharmaceuticals (STOCK:ATNM) Could Potentially Treat Relapsed or Refractory Acute Myeloid Leukemia

  • Actinium Pharmaceuticals could potentially treat Relapsed or Refractory Acute Myeloid Leukemia with a promising drug candidate. 
  • Actinium’s Leukemia drug candidate reportedly has a remission rate of approximately 86% with around 71%.
  • The company holds significantly more assets than debt on its balance sheet, is funded way more through equity than debt, and with an Altman Z-Score of 11.8, shows robust financial health with little bankruptcy risk.
  • The stock has surged over 107% since it bottomed in April, and has an analyst upside target of as high as 116.6%. 
  • The stock may be at an attractive entry point, with bullish technical indicators in the short-term, mid-term, and long-term.


Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity

Meeting an unmet medical need is the Holy Grail for pharmaceutical companies.

Take the case of Actinium Pharmaceuticals (STOCK:ATNM) for example.

While COVID gets all the media attention nowadays, there is still a significant unmet medical need for the treatment of Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML).

Unfortunately, standard therapies for R/R acute myeloid leukemia just are not sufficient.

According to the National Center for Biotechnology Information, many patients either do not achieve complete response (CR) after CR or relapse. Furthermore, although 70-80% of patients achieve CR, many patients are refractory to, or relapse, following treatment.(1)

There is also a “lack of a uniform treatment strategy for this group, with the exception of allogeneic hematopoietic transplantation (HCT) as the only potentially curative treatment option for patients achieving a second complete remission.”(2)

Actinium Pharmaceuticals Could Potentially Solve This Unmet Need

Clinical trials for Actinum’s Actimab-A CLAG-M combination have been very encouraging. With this treatment, Actinum reported a remission rate of 86%. 71% of patients also achieved negative minimal residual disease status with the second dose of Actimab-A CLAG-M Combination.(3)

All patients in the third dosing cohort also completed treatment with a 0.75 uCi/kg dose of Actimab-A followed by CLAG-M and have already cleared their initial safety evaluation.(4) This cohort is expected to be the final cohort of the planned Phase 1 dose escalation trial.

Both investors and the medical community are eagerly anticipating the expected release of clinical results by the end of the year.

Actinium’s Remission Rates Appear Far Better Than Competitors’

According to Actinium’s study results, remission rates appear to be far better than competing therapies that have already been approved for treatment.

Actinium Pharmaceuticals has shown an overall response rate of 86% in tests, as compared to:(6)

  • 68% with g.ilteritinib (X.ospata)
  • 64% with v.enetoclax (V.enclexta) plus h.ypomethylating agents,
  • 40% with e.nasidenib (I.dhifa),
  • 19% with v.enetoclax alone, and
  • 17% with a.zacytidine alone

Actinium Pharmaceuticals (STOCK:ATNM), has Even More Exciting Treatments in the Works

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops ARC’s or Antibody Radiation-Conjugates. This combines the targeting ability of antibodies with the killing ability of radiation therapies.

Some of the things Actinium has in the works are:

  • Lomab-B. This may be Actinium’s lead asset, and is in a pivotal Phase 3 clinical trial. This is being used as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory Acute Myeloid Leukemia (AML) prior to receiving a bone marrow transplant (BMT), also known as a hematopoietic transplant or HSCT.(7)
  • Actinium is also developing a multi-disease, multi-target pipeline of clinical-stage ARC’s targeting the antigens CD45 and CD33. The goal is for this to become a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including AML or Acute Myeloid Leukemia, MDS or Myelodysplastic Syndrome MM or Multiple Myeloma.
  • The company’s proprietary AWE or Antibody Warhead Enabling technology platform has also garnered attention. Actinium’s intellectual property portfolio of over 100 patents, finite knowledge, and collective research and expertise in the field, plan to be leveraged in order to construct and study novel ARC’s and ARC combinations to bolster its pipeline for strategic purposes.
  • Actinium has also launched a brand new research and development (R&D) facility in New York City. This new research facility expands Actinium’s internal R&D capabilities and claims to focus on developing novel ARC candidates, ARC therapeutic combination strategies, and supporting AWE platform research collaborations.

Actinium’s Fundamentals are Strong…and Analysts Can’t Get Enough

For an experimental pharmaceutical company, Actinium’s fundamentals are quite enticing…and analysts are noticing.

The company, first and foremost, is extremely underlevered. It holds way more cash than debt on its balance sheet, and for a growing, experimental company, this is huge. Its Debt / Equity ratio of 1.9%, Current Ratio of 10.5x, and Quick Ratio of 10.3x are outstanding numbers that depict the company’s financial health. It appears to fund itself more through equity than debt, and has more than enough assets to fulfill its obligations.

The company’s Altman Z-Score of 11.9 shows financial health and a very low bankruptcy risk. Ideally a company wants a Z-Score of 3.0 or higher, and no lower than 1.8. The fact that Actinium’s Z-Score is nearly 4 times higher than the ideal amount speaks volumes.

Furthermore, due to its small float, this is a stock that surges on good news. In fact, the stock, since it bottomed in the end of April, has skyrocketed by over 107%, and has seen a massive price tick over the last 6 months.

But don’t just take their financials’ word for it. Analysts are in love with this stock and can’t stop gushing over it.

H.C. Wainwright for example recently initiated a buy rating on the stock.(7) Additionally, according to the Wall Street Journal the stock has a low price target of $25.00, a median price target of $32.50, and a high price target of $65.00.(8) To put that in perspective, the stock is currently trading at only $11.28 a share! With the high price target, this gives the stock a consensus analyst upside of nearly 116.6%. 

Additionally, analysts are forecasting the company’s next quarterly EPS to be -$0.46- a gain of 61.67% from the prior-year quarter.(9)

Analysts are bullish on the company’s interim clinical data on Actimab, and believe that its capital increase in April potentially eliminates the risk of additional shareholder dilution. Furthermore, this increase in capital could even provide enough cash to cover the early stages of commercialization.

Actinium’s Technicals Show Bullish Signals Too

After Actinium’s stock tested a high of approximately $18.83, the stock pulled back to about $7 where it found strong support dating back to early February 2020.

Now at approximately $11.28, the stock appears to have regained momentum, especially with all of the good news hitting the headlines. If more positive news continues to be released, the stock could very well test its prior high of $18.83.

Additionally, the stock is showing strong technical indicators based on its:(10)

  • 20- and 50-day moving average
  • 100 to 200-day moving averages
  • 20-50 day MACD Oscillator
  • 20-200 day MACD Oscillator
  • 50-200 day MACD Oscillator
  • 100-200 day moving average

Strong Leadership, Strong Results (STOCK:ATNM)

Successful companies tend to possess common traits, and one of those traits is a strong management team. Actinium Pharmaceuticals (STOCK:ATNM) has that ground covered.

Sandesh Seth
Chief Executive Officer and Chairman of the Board

Mr. Seth has 20+ years’ experience in investment banking (Laidlaw & Co., Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and in the pharmaceutical industry (Pfizer, Warner-Lambert, SmithKline) in strategic planning, business development and R&D project management. Formerly, Mr. Seth was the Chairman of the Board of Relmada Therapeutics Inc., a publicly listed, specialty pharmaceuticals company focused on pain therapeutics. Mr. Seth has received his M.S. degree in Pharmaceutical Science from the University of Oklahoma and his M.B.A. with a concentration in finance from NYU Stern.

C. David Nicholson, B.S., Ph.D
Lead Independent Director

C. David Nicholson, BS, PhD., is lead Independent Director of Actinium Pharmaceuticals Inc. He is Chief R&D Officer at Allergan and has served in this role since March 2015. Dr. Nicholson joined Allergan (then Actavis) in August 2014 as Senior Vice President, Global Brands R&D. Previously he was on the Executive Committee of Bayer CropScience as Head of Research & Development responsible for the integration of the company’s R&D activities into one global organization. Dr. Nicholson graduated in pharmacology, earning his B.Sc. from the University of Manchester (1975) and his Ph.D. from the University of Wales (1980). Between 1978 and 1988, Dr. Nicholson worked in the pharmaceutical industry for the British company Beecham-Wülfing in Gronau, Germany. The main emphasis of his activities as group leader in a multidisciplinary project group was the development of cardiovascular drugs. From 1988-2007, Dr. Nicholson held various positions of increasing seniority in the UK, the Netherlands and the USA with Organon a Business Unit of Akzo Nobel. Ultimately, he became Executive Vice President, Research & Development, and member of the Organon Executive Management Committee.

He implemented change programs, leading to maximizing effectiveness in research & development, ensuring customer focus and the establishment of a competitive pipeline of innovative drugs. In 2007, Dr. Nicholson transferred to Schering-Plough, Kenilworth, New Jersey, USA, as Senior Vice President, responsible for Global Project Management and Drug Safety. From 2009 to December 2011, he was Vice President Licensing and Knowledge Management at Merck in Rahway, New Jersey, USA, reporting to the President of Merck R&D. As an integration team member, David Nicholson played a role in the strategic mergers of Organon BioSciences, the human and animal health business of Dutch chemical giant Akzo-Nobel, and Schering-Plough in 2007 as well as of Schering-Plough and Merck in 2009. C. David Nicholson is presently on the Board of multiple biotechnology companies, including Actinium Pharmaceuticals, Inc.

Ajit Shetty, Ph.D.

Dr. Shetty is a pharmaceutical industry executive with 36 years of experience at Johnson & Johnson (J&J) and its subsidiary Janssen. Most recently Dr. Shetty served as the Head of Enterprise Supply Chain at J&J where he was responsible for the transformation and optimization of J&J’s global supply chain.

Dr. Shetty joined Janssen Pharmaceutica, Inc. in 1976 ultimately rising to the position of President in 1986 where he led the establishment of Janssen’s business in the U.S. From 1999 to 2008 he was Managing Director of Janssen Pharmaceutica, during this time the Janssen Group of companies’ global sales grew from $1 billion to $8 billion, and from 2004 until 2012 he was Chairman of the Board of Directors. In Dr. Shetty’s most recent role at Johnson & Johnson he was head of Enterprise Supply Chain, where he reported to the CEO and was responsible for the transformation and optimization of Johnson & Johnson’s supply chain. Dr. Shetty earned a Ph.D. in Metallurgy and B.A. Natural Sciences from Trinity College, Cambridge University and a Master of Business Administration from Carnegie Mellon University.

In 2007, Dr. Shetty was bestowed the title of Baron by King Albert II of Belgium for his exceptional merits. He is a member of the Board of Trustees of Carnegie Mellon University, serves on the Board of Governors for GS1 (Global Standards) in Belgium and formerly served on the Corporate Advisory Board of the John Hopkins Carey Business School. In 2016, Dr. Shetty was named as Chairperson of the Vlaams Instituut voor B.iotechnologie (VIB), a Belgium based life sciences research institute focused on translating scientific results into pharmaceutical, agricultural and industrial applications. In addition, he was elected Manager of the Year in 2004 in Flanders and received a Life-Time Achievement Award in India in 2010.

Richard l. Steinhart

Richard I. Steinhart has served as our Director and Chairman of the Audit Committee since November 2013. Mr. Steinhart is also a member of our Corporate Governance Committee. Mr. Steinhart has significant financial and strategic experience in the biotechnology and medical device industries. Currently, he is Vice President and Chief Financial Officer of BioXcel Therapeutics. Previously, Richard served as Vice President and CFO at Remedy Pharmaceuticals, Inc., until it sold its only asset, CIRARA, to Biogen for $120M plus earn-outs. Prior to joining Remedy Pharmaceuticals, Mr. Steinhart served as an independent consultant to biotechnology and medical device companies. Previously, Mr. Steinhart was the Senior Vice President, Finance and Chief Financial Officer of MELA Sciences. Prior to joining MELA Sciences, Mr. Steinhart held a variety of senior-level positions at Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies, Emisphere Technologies, Inc., and CW Group, Inc., a venture capital firm focused on medical technology. He began his career at PriceWaterhouseCoopers.

Jeffrey W. Chell, M.D.

Jeffrey W. Chell, M.D., became the National Marrow Donor Program’s Chief Executive Officer in 2000 where he led the NMDP through transformational growth as the Be The Match Registry tripled to more than 12 million donors, the number of transplants facilitated has grown five fold to over 6,400 annually, and blood transplants and revenue more than tripled to nearly $400 million per year. Dr. Chell is the co-founder and served as Executive Director of CIBMTR ®, the leading research program in the field contributing over 70 research publications per year in peer-reviewed journals. In addition, he served as co-chair of Bone Marrow Donors Worldwide (BMDW) during its IT transformation project, improving revenues and reducing costs. He then oversaw the merger of BMDW with World Marrow Donor Association and EuroCord. Dr. Chell currently serves as Chair of CLR Insurance, a captive insurance company domiciled in the Cayman Islands. Prior to joining the NMDP, he served as president, Allina Medical Clinics, a 450-physician multi-specialty medical group from 1994 to 1999. Prior to that he practiced Internal Medicine in Minneapolis and in the U.S. Air Force Medical Corps.

Dr. Chell received his M.D. from the University of Minnesota and his training in Internal Medicine at the University of Wisconsin, Madison. Dr. Chell is a member of the American Society of Hematology and a member of the American Society of Blood and Marrow Transplantation. He has received multiple honors including the 2018 Public Service award of the ASBMT, 2017 Most Admired CEO by the Minneapolis/St. Paul Business Journal, 2010 Healthcare Executive of the Year by the Minneapolis/St. Paul Business Journal, 2017 Bone Marrow Foundation Service Award.

The Top 5 Reasons to Consider Actinium Pharmaceuticals (STOCK:ATNM)

  1. Actinium Pharmaceuticals could potentially have a treatment R/R AML- an unmet medical need. Its Actimab-A drug candidate reported a remission rate of approximately 86% with around 71% of patients in clinical trials.
  2. Actinium’s lead asset is Lomab-B, which is in a pivotal Phase 3 clinical trial as an induction and conditioning agent in patients over the age of 55 with R/R AML.
  3. The company holds significantly more assets than debt on its balance sheet, is funded way more through equity than debt, and with an Altman Z-Score of 11.8, shows robust financial health with little bankruptcy risk.
  4. The stock has surged over 107% since it bottomed in April, and has an analyst upside target of as high as 116.6%.
  5. The stock may be at an attractive entry point, with bullish technical indicators in the short-term, mid-term, and long-term.

Source 1: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486485/Source 2: https://www.hematologyadvisor.com/home/topics/leukemia/treating-relapsed-refractory-acute-myeloid-leukemia/

Source 3: https://ir.actiniumpharma.com/press-releases/detail/365/actinium-pharmaceuticals-announces-successful-completion-of

Source 4: https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-successful-completion-of-planned-phase-1-actimab-a-clag-m-combination-trial-in-patients-with-relapsedrefractory-aml-at-medical-college-of-wisconsin-301129880.html

Source 5: https://ashpublications.org/blood/article-abstract/136/9/1023/460740/How-I-treat-relapsed-or-refractory-AML?redirectedFrom=fulltext

Source 6: https://d1io3yog0oux5.cloudfront.net/_a97b700c6679b4e86cb751a3855e3a5e/actiniumpharma/db/193/977/pdf/Targeted+Oncology+Article+86%25+Rem+Rate+3.20.pdf

Source 7: https://www.actiniumpharma.com/about

Source 8: https://www.wsj.com/market-data/quotes/ATNM/research-ratings

Source 9: https://finance.yahoo.com/news/actinium-pharmaceuticals-atnm-gains-lags-224510410.html

Source 10: https://www.barchart.com/stocks/quotes/ATNM/opinion

Legal Disclosure

This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.

We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

Pursuant to an agreement between TD Media LLC and Venado Media LLC , TD Media LLC has been hired for a period beginning on 10/21/20 and ending on 10/22/20 to publicly disseminate information about (ATNM) via digital communications. We have been paid ten thousand USD via bank wire transfer. We own zero shares of (ATNM).

Pursuant to an agreement between TD Media LLC and Legends Media LLC , TD Media LLC has been hired for a period beginning on 11/23/20 and ending on 12/4/20 to publicly disseminate information about (ATNM) via digital communications. We have been paid an additional forty five thousand USD via bank wire transfer. We own zero shares of (ATNM). To date we have been paid fifty five thousand dollars USD via bank wire transfer to disseminate information about (ATNM) via digital communications.